Influence of pharmacist intervention on prescribing of angiotensin-converting-enzyme inhibitors, angiotensin II-receptor blockers, and aspirin for diabetic patients

February 2010
American Journal of Health-System Pharmacy;2/15/2010, Vol. 67 Issue 4, p290
Academic Journal
Purpose. The influence of pharmacist intervention on the prescribing of angiotensin-converting-enzyme (ACE) inhibitors, angiotensin II-receptor blockers (ARBs), and aspirin for patients with diabetes was evaluated. Methods. A retrospective chart review was performed for diabetic patients seen in a family medicine clinic. Patients were included in the analyses if they were 18-88 years old, had a diagnosis of type 1 or type 2 diabetes, had been seen in the family medicine clinic between July 2006 and October 2008, and had received a consultation by pharmacy services. All selected charts were reviewed to assess appropriate use of ACE inhibitor, ARB, and aspirin therapy, as recommended by American Diabetes Association (ADA) guidelines, before and after pharmacist intervention. Typical pharmacist interventions consisted of direct consultation with the prescriber and therapeutic education sessions conducted by pharmacy personnel. All patients were seen and evaluated by pharmacy personnel before meeting with the prescriber. Results. Before pharmacist intervention, 41 (59%) of 70 patients were receiving appropriate ACE inhibitor or ARB therapy and 24 (34%) of 71 patients were receiving appropriate aspirin therapy as recommended by ADA. After pharmacist intervention, 63 (90%) of 70 patients were receiving appropriate ACE inhibitor or ARB therapy and 48 (68%) of 71 patients were receiving appropriate aspirin therapy as recommended by ADA (p < 0.0001 for both differences). Conclusion. A pharmacy intervention program in a primary care setting was associated with a significant increase in prescriber adherence to ADA guidelines for ACE inhibitor or ARB therapy and for aspirin therapy in diabetic patients.


Related Articles

  • Correction.  // American Family Physician;12/15/2012, Vol. 86 Issue 12, p1096 

    A correction to an article about the effectiveness of ACE inhibitors and angiotensin II receptor blockers that was published in the July 15, 2012 issue of "The Clinical Evidence Handbook" is presented.

  • The Impact of ACE Inhibitors or Angiotensin II Type 1 Receptor Blockers on the Development of New-Onset Type 2 Diabetes. Gillespie, Effie L.; White, C. Michael; Kardas, Michael; Lindberg, Michael; Coleman, Craig I. // Diabetes Care;Sep2005, Vol. 28 Issue 9, p2261 

    OBJECTIVE -- Angiotensin II has been shown to increase hepatic glucose production and decrease insulin sensitivity. Patients who utilize either an ACE inhibitor (ACEI) or angiotensin receptor blocker (ARB) may experience a decreased incidence of new-onset type 2 diabetes. RESEARCH DESIGN AND...

  • HYPERTENSION DRUGS FOR HIGH-RISK PATIENTS.  // Aging Well;Spring2011, Vol. 4 Issue 2, p5 

    The article focuses on the use of angiotensin II receptor blockers (ARB) and angiotensin converting enzyme (ACE) inhibitors in treating high-risk hypertension and diabetes patients. It notes that using ARBs have lower incidence for patients being hospitalized for congestive heart failure. It...

  • The Clinical Significance of New-Onset Diabetes Mellitus in Hypertension. Verdecchia, Paolo; Angeli, Fabio; Garofoli, Marta; Reboldi, Gianpaolo // High Blood Pressure & Cardiovascular Prevention;Feb2008, Vol. 15 Issue 1, p1 

    Several intervention trials found that some antihypertensive drugs, mostly ACE inhibitors, calcium-channel blockers and angiotensin II receptor blockers, are associated to a lesser risk of developing diabetes mellitus in comparison with other drug classes, including diuretics and β-blockers....

  • The Effect of Antihypertensive Agents on New-Onset Diabetes Mellitus: Time to Amend the Guidelines? Aksnes, Tonje Amb; Kjeldsen, Sverre Erik; Mancia, Giuseppe // American Journal of Cardiovascular Drugs;2006, Vol. 6 Issue 3, p139 

    Recent large hypertension trials have shown great differences in incidence of new-onset diabetes mellitus among patients receiving different antihypertensive drug therapies. The incidence of diabetes is unchanged or increased by the use of thiazide diuretics and β-adrenoceptor antagonists...

  • Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria. Tse, K. C.; Li, F. K.; Tang, S.; Tang, C. S.-O.; Lai, K. N.; Chan, T. M. // Lupus;2005, Vol. 14 Issue 12, p947 

    Angiotensin-converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) reduces proteinuria and the rate of renal function deterioration in diabetic nephropathy and other glomerular diseases, but its role in quiescent lupus nephritis has not been established. We conducted a...

  • The kallikrein-kinin system in diabetic nephropathy. Tomita, Hirofumi; Sanford, Ryan B; Smithies, Oliver; Kakoki, Masao // Kidney International;Apr2012, Vol. 81 Issue 8, p733 

    Diabetic nephropathy is the major cause of end-stage renal disease worldwide. Although the renin-angiotensin system has been implicated in the pathogenesis of diabetic nephropathy, angiotensin I-converting enzyme inhibitors have a beneficial effect on diabetic nephropathy independently of their...

  • Economic evaluations of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in type 2 diabetic nephropathy: a systematic review. Yunyu Huang; Qiyun Zhou; Haaijer-Ruskamp, Flora M.; Postma, Maarten J. // BMC Nephrology; 

    Background Structured comparison of pharmacoeconomic analyses for ACEIs and ARBs in patients with type 2 diabetic nephropathy is still lacking. This review aims to systematically review the cost-effectiveness of both ACEIs and ARBs in type 2 diabetic patients with nephropathy. Methods A...

  • Angiotensin II-receptor blockers: will they replace angiotensin-converting enzyme inhibitors in the treatment of hypertension? Kaplan, N M // Journal of Human Hypertension;Apr2000 Supplement, Vol. 14 Issue 4, pS87 

    In the past few years, angiotensin II-receptor blockers have become available and are being heavily marketed and increasingly used. In various ways they differ from angiotensin-converting enzyme inhibitors (ACEIs). Until outcome data are available, they should continue to be used primarily in...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics